Polyphor Proceeding With POL7080 Testing After Roche Hands Antibiotic Back
This article was originally published in Scrip
Executive Summary
Polyphor Ltd says it will proceed alone with Phase II testing of its macrocycle antibiotic candidate POL7080 after Roche Holdings AG decided it would take too long to develop the investigational drug for treating patients with severe Pseudomonas aeruginosa infections, and so handed it back to the Swiss biotech.
You may also be interested in...
Summit Completes 2017 With Discuva Buy
After good news on the funding front in the 2017 third quarter, UK biotech Summit Therapeutics has completed the year on a high, acquiring fellow UK biotech Discuva to add a novel antibiotic discovery platform to its expertise.
Roche Goes Back To Nature With Warp Drive Antibiotic Pact
The Swiss major is paying up to $387m to get access to potential natural antibiotics that have not been analyzed previously, 'owing to historical technology limitations.'
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.